Ra Pharma (RARX) PT Raised to $34 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria
December 4, 2017 7:00 AM EST
- Dosing Complete, Primary Endpoint Met in Eculizumab Naïve Cohort
(p=0.002 for LDH reduction)
- Switch Cohort: Interim Data
Demonstrate Successful Switching from Eculizumab
- Phase 2
Enrollment Complete in All Cohorts
- Company to Host
Conference Call Today, December 4, at 8:00am ET to Discuss Interim Data
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:... More
